Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

Merck & Co (MSD), Alexion ... MSD reported the discontinuation of its two Phase III clinical trials for Keytruda (pembrolizumab) in August 2024.

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...